High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease

Vasa - European Journal of Vascular Medicine

Volumn 45, Issue 2, 2016, Pages 155-161

  Bernlochner, Isabell ^a   Jaitner, Juliane ^a   Fries, Verena ^a   Dommasch, Michael ^a   Mayer, Katharina ^b   Ott, Ilka ^b   Langwieser, Nicolas ^a   Fusaro, Massimiliano ^b   Laugwitz, Karl Ludwig ^a,c   Kastrati, Adnan ^b,c   Ibrahim, Tareq ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

High platelet reactivity; Outcomes; Peripheral artery disease; Restenosis; Target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE HEART INFARCTION; AGED; ARTICLE; ATHERECTOMY; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; ECHOGRAPHY; ENDOVASCULAR SURGERY; EVALUATION AND FOLLOW UP; FEMALE; FEMOROPOPLITEAL BYPASS; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; RESTENOSIS; THROMBOCYTE AGGREGATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CHI SQUARE DISTRIBUTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ACTIVATION; TIME FACTOR; TREATMENT OUTCOME;

AGED; ASPIRIN; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROPORTIONAL HAZARDS MODELS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84973440901     PISSN: 03011526     EISSN: 16642872     Source Type: Journal    
DOI: 10.1024/0301-1526/a000510     Document Type: Article

References (26)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral artery disease (lower extremity, renal, mesenteric, and abdominal aortic). J Am Coll Cardiol 2006;47: 1239 - 1312.
2. Norgren L, Hi att WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral artery disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 Suppl 1: S1 - 75.
3. Sibbing D, Br aun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849 - 856.
4. Aradi D, Komo csi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160: 543 - 551.
5. Spiliopoulos S, Pastromas G, Katsanos K, et al. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 2013; 61: 2428 - 2434.
6. Gremmel T, St einer S, Seidinger D, et al. In vivo and proteaseactivated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 2014; 111: 474 - 482.
7. Unterberg C, Sandrock D, Nebendahl K, et al. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol 1995; 26: 1747 - 1754.
8. Evans DJ, Jac kman LE, Chamberlain J, et al. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009;119:116 - 122.
9. Taylor RR, Gi bbons FA, Cope GD, et al. Effects of low-dose aspirin on restenosis after coronary angioplasty. Am J Cardiol 1991; 68: 874 - 878.
10. Kastrati A, Schuhlen H, Hausleiter J, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997; 96: 462 - 467.
11. Schulz S, Si bbing D, Braun S, et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am Heart J 2010; 160: 355 - 361.
12. Penz SM, Ber nlochner I, Toth O, et al. Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J 2010; 8: 9.
13. TIMI Study G roup. Definitions used in TIMI trials. Available at: http://www.timi.org. Accessed August 1, 2008.
14. Stone GW, Wi tzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614 - 623.
15. von Hundelsh ausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27 - 40.
16. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28: 1643 - 1651.
17. Patil SB, Ja ckman LE, Francis SE, et al. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol 2010;30: 2385 - 2391.
18. Acute platel et inhibition with abciximab does not reduce instent restenosis (ERASER study). The ERASER Investigators. Circulation 1999; 100: 799 - 806.
19. Savage MP, G oldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92: 3194 - 3200.
20. Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2010; 106: 1208 - 1211.
21. Mehta SR, Ta nguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus lowdose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENTOASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233 - 1243.
22. Werner M, Sc heinert D. Drug eluting devices for critically ill patients: can we apply lessons learned from the treatment of peripheral artery disease? Adv Drug Deliv Rev 2014; 77: 32 - 39.
23. Koizumi A, K umakura H, Kanai H, et al. Ten-year patency and factors causing restenosis after endovascular treatment of iliac artery lesions. Circ J 2009;73:860 - 866.
24. Kudo T, Chan dra FA, Ahn SS. Long-term outcomes and predictors of iliac angioplasty with selective stenting. J Vasc Surg 2005; 42: 466 - 475.
25. Laird JR, Ka tzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010; 3: 267 - 276.
26. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879 - 1888.